NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
![NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?](https://www.ohe.org/wp-content/uploads/2023/09/andrew-butler-aUu8tZFNgfM-unsplash-scaled.jpg)
This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year by the pharmaceutical industry. Factors identified as important include a trend towards targeting more complex and difficult diseases, the need to adapt to dramatic changes in scientific knowledge and in R&D approaches, and substantial changes in both the regulatory and marketing climates.
In addition to describing overall trends, Prof Riccaboni also compares the R&D performance of companies based in the US and Europe, and a set of “global” companies. He finds that the global companies rank highest on R&D productivity and equal US companies in the market value of their new drugs.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!